METABASIS STARTS DIABETES STUDY

Metabasis Therapeutics has initiated a Phase I clinical trial of MB07803, a potential treatment for patients with Type 2 diabetes. MB07803 is the second of a new class of drugs discovered by Metabasis that regulates glucose production in the liver by inhibiting an enzyme known as fructose 1,6 bisphosphatase (FBPase), a key component of the pathway responsible for the production of glucose known as the gluconeogenesis pathway.